Actuate Therapeutics (ACTU) investor relations material

Executive summary

• Focused on developing elraglusib, a GSK-3β inhibitor, for difficult-to-treat cancers, with both IV and oral formulations advancing in clinical trials.

• Phase 2 mPDAC study met its primary endpoint, showing significant survival benefit for elraglusib plus chemotherapy versus control.

• Over 500 patients treated to date; FDA clearance received for Phase 1/2 study of oral elraglusib.

Financial highlights

• Net loss for Q1 2026 was $5.6 million, an improvement from $6.3 million in Q1 2025.

• Operating expenses decreased to $5.7 million from $6.4 million year-over-year, driven by lower clinical study and manufacturing costs.

• Cash and cash equivalents were $8.1 million as of March 31, 2026, down from $13.2 million at year-end 2025.

• Working capital stood at $3.8 million at quarter-end.

Outlook and guidance

• Current cash is expected to fund operations only through July 2026; additional capital will be required.

• Plans to seek further financing through equity offerings, debt, or other sources; inability to secure funding may require scaling back or ceasing operations.

• Research and development expenses expected to increase as clinical programs expand, contingent on funding.